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SUMMARY

Duffy antigen receptor for chemokines (DARC) expressed on red blood cells (RBCs) influences plasma
levels of HIV-1-suppressive and proinflammatory
chemokines such as CCL5/RANTES. DARC is also
the RBC receptor for Plasmodium vivax. Africans with
DARC 46C/C genotype, which confers a DARCnegative phenotype, are resistant to vivax malaria.
Here, we show that HIV-1 attaches to RBCs via
DARC, effecting trans-infection of target cells. In African Americans, DARC 46C/C is associated with
40% increase in the odds of acquiring HIV-1. If extrapolated to Africans, 11% of the HIV-1 burden in
Africa may be linked to this genotype. After infection
occurs, however, DARC-negative RBC status is associated with slower disease progression. Furthermore,
the disease-accelerating effect of a previously described CCL5 polymorphism is evident only in
DARC-expressing and not in DARC-negative HIV-infected individuals. Thus, DARC influences HIV/AIDS
susceptibility by mediating trans-infection of HIV-1
and by affecting both chemokine-HIV interactions
and chemokine-driven inflammation.
INTRODUCTION
Host genetic polymorphisms contribute to interindividual variation in susceptibility to acquiring HIV-1 infection, the degree of infectiousness to others (as reflected by the viral load), and rates of
disease progression. Such polymorphisms might also contribute
to significant interpopulation differences in HIV-1 prevalence
(Gonzalez et al., 1999, 2005; Schliekelman et al., 2001; Sullivan
et al., 2001; Winkler et al., 2004), since sexual behavior and other

social factors do not fully explain regional variations of the HIV-1
pandemic (Buve, 2002; Kinoshita-Moleka et al., 2007; Weiss and
McMichael, 2004). Thus, identification of transmission and disease modifying polymorphisms that are found more frequently
in specific populations may provide insight into the host genetic
factors that contribute to the heterogeneity of HIV-AIDS
pandemic and has broad public health relevance, as failure to
account for such polymorphisms may confound the evaluation
of therapeutics, microbicides, and vaccines (Kellam and Weiss,
2006; Pepin, 2005).
Host genetic influence on HIV-AIDS susceptibility by a polymorphism that is differentially distributed between populations
is best illustrated by the effects of the European-specific 32 bp
deletion (D32) in the gene for CC chemokine receptor 5 (CCR5),
which is the major coreceptor for R5 strains of HIV-1 that represent the majority of transmissible viruses (Lama and Planelles,
2007). The CCR5-D32/D32 genotype abrogates cell-surface expression of CCR5 and is associated with profound resistance to
HIV infection. Heterozygosity for CCR5-D32 is associated with
a reduction in risk of acquisition of R5 HIV and with a trend toward a slower rate of progression to AIDS (Gonzalez et al.,
1999; Lama and Planelles, 2007; Mangano et al., 2001). It has
been proposed (Schliekelman et al., 2001; Sullivan et al., 2001)
that the absence of the protective CCR5-D32/D32 genotype
might have contributed to the accelerated spread of HIV in
African populations, although this notion is debatable considering the relatively low prevalence of this genotype in European
populations (1%–3%).
Other as-yet-undefined host factors are expected to have
population-specific effects on HIV-AIDS and possibly also contribute to the generally high prevalence of HIV in sub-Saharan
Africa. Defining whether there is a genetic basis for the higher incidence of HIV in Africa is especially relevant for two reasons.
First, racial differences in incidence and outcome of inflammatory disorders such as sepsis have been observed (Martin
et al., 2003). Second, recent studies suggest that compared to
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individuals of European descent, people of African descent
might have a genetic profile that favors a ‘‘high-expression profile’’ of proinflammatory cytokines and a ‘‘low-expression profile’’ of anti-inflammatory cytokines (Mayr et al., 2008; Ness
et al., 2004). In light of the aforementioned, and because of the
importance of the chemokine system in inflammation and HIVAIDS pathogenesis (Murphy et al., 2000) and the reasons outlined below, in this study we focused on the impact of variation
in the gene encoding Duffy Antigen Receptor for Chemokines
(DARC) on risk of acquiring HIV and on disease progression.
DARC is expressed mainly on red blood cells (RBCs) as well as
on vascular endothelial and neuronal cells (Hadley and Peiper,
1997). DARC is characterized by its ability to bind a wide array
of proinflammatory chemokines (Comerford et al., 2007; Gardner
et al., 2004; Rot, 2005) including CCL5 (RANTES), which is highly
effective in suppressing HIV-1 replication. However, binding of
chemokines to DARC on RBCs does not trigger a signaling cascade because DARC lacks the G protein-signaling domain
(Comerford et al., 2007; Rot, 2005). Instead, the promiscuous
binding of chemokines to DARC is viewed as a mechanism for
regulating plasma levels of chemokines (Fukuma et al., 2003;
Jilma-Stohlawetz et al., 2001; Mayr et al., 2008) and, consequently, inflammation (Lee et al., 2006; Mantovani et al., 2006).
The observation that DARC substantially influences erythrocyte-bound and plasma chemokine concentrations following
administrations of endotoxin (lipopolysaccharide, LPS) (Mayr
et al., 2008) is relevant in light of the recent association between
LPS and immune activation and HIV pathogenesis (Douek,
2007). Thus, these characteristics of DARC suggest that it could
also modulate the levels of HIV-suppressive chemokines and
inflammation observed during HIV disease.
It has been proposed that HIV might bind to RBCs by two different mechanisms. First, it was found that HIV-1 can bind to
RBCs in vitro and that this binding is mediated through DARC
(Lachgar et al., 1998). Supporting this, HIV bound to RBCs has
been observed in HIV-infected subjects who have undetectable
plasma viral load during highly active antiretroviral therapy
(HAART), and this is associated with a poor clinical outcome
(Hess et al., 2002). The second is by indirect association of
opsonised HIV particles via HIV/anti-HIV immune complexes
and complement factor c3b binding to CR1 (CD35) (Banki
et al., 2006; Horakova et al., 2004). To further evaluate the impact
of DARC on HIV-AIDS pathogenesis, in this study we investigated whether a polymorphism in DARC that has been intensively scrutinized in the context of malaria (Tournamille et al.,
1995) also influences HIV-AIDS susceptibility.
The single nucleotide polymorphism (SNP) at the 46 position
(T46C) in the promoter of DARC is widely prevalent in populations of African descent. The 46C allele disrupts the binding
site for the erythroid-specific transcription factor GATA-1, and
consequently, the 46C/C DARC promoter genotype results in
selective loss of expression of DARC on RBCs but not other
cell types on which DARC is expressed (Tournamille et al.,
1995). Interestingly, this polymorphism influences pathogenesis
of another major infectious disease, malaria caused by Plasmodium species. As DARC serves as the receptor on RBCs for merozoites of Plasmodium vivax (Horuk et al., 1993), Africans with
the DARC 46C/C genotype are highly resistant to malaria
caused by this Plasmodium strain (Tournamille et al., 1995). It

is noteworthy that malaria influences the spread of HIV infection,
and these two infections together contribute to significant morbidity and mortality in regions devastated by the HIV epidemic
(Abu-Raddad et al., 2006).
Here, we show that DARC mediates the binding of HIV to RBCs
and the subsequent transfer of virus to HIV-1 target cells. We coupled these in vitro studies with a detailed genetic epidemiological
analysis to determine whether the T46C polymorphism in
DARC affects susceptibility to HIV-AIDS of African Americans.
Our results affirm that it does, as well as demonstrating a complex
interaction between DARC, chemokines, and HIV in vivo.
RESULTS
DARC Binds and Transfers HIV-1 to Target Cells
DARC+ and DARC RBCs (as in Figure 1A) were incubated with
various HIV-1 strains, washed, and then cocultured with HIV-susceptible NP2 cells that express the HIV receptor CD4 as well as
either CCR5 or CXCR4 as described in Experimental Procedures.
The extent of carriage of HIV by RBCs differed according to coreceptor usage (R5, R5X4, and X4) (Figure 1B). In general, transfer
of R5 strains was less than 1% of the infecting inoculum, whereas
it was significantly greater for R5X4 and X4 strains, approaching
50% for SF2, an X4 strain (Figure 1B). Of these isolates, SL-2
(R5), 2076, 2028 (R5X4), and 2044 (X4) are all primary isolates
that have been minimally passaged in peripheral blood mononuclear cells (PBMCs) (Simmons et al., 1996). Similar HIV transfer
results were obtained when PBMCs were used as target cells,
and HIV reverse transcriptase (RT) activity in the cell supernatants was used as measure of infection (Figure 1C).
DARC+ RBCs transferred HIV-1 strains (R5, X4, and R5X4)
with 5- to 12-fold more efficiency than DARC RBCs (Figure 1D),
suggesting that DARC provided an HIV-1 binding site to human
RBCs. To establish that these effects were mediated specifically
by DARC, we investigated whether a DARC antibody or chemokine ligands for DARC can compete for the attachment/binding
of HIV-1 to DARC on RBCs. The DARC ligands CXCL8 (IL-8)
and CCL5 (RANTES) significantly reduced the attachment of
HIV-1 to DARC+ RBCs, whereas CCL3 (MIP-1aS), which is not
a ligand for DARC, had minimal effects (Figures 1E and 1F). Interestingly, even R5 strains (SL-2 and BAL) that demonstrated less
efficient transfer (Figure 1B) to NP2/CD4/CCR5 cells were sensitive to blockade by CXCL8 (Figure 1F). Monoclonal antibody
directed against the DARC epitope Fy6 (anti-Fy6) moderately
outcompeted HIV attached to RBCs (Figure 1E). Collectively,
these findings demonstrated that HIV-1 virions bind to RBCs in
vitro and that RBCs mediate the transfer and infectivity of
RBC-bound HIV to target cells predominantly via DARC. The
attachment and/or transfer process appeared to be more efficient for R5X4 and X4 HIV strains than R5 strains.
As shown in Figure 1B, R5 strains of HIV-1 were much less efficiently transferred by RBCs than those with X4 tropism or dual
tropism, probably because the envelope protein conformation of
R5 strains occludes the coreceptor binding site on gp120. Interaction of gp120 with CD4 causes a conformational change that
exposes these hidden epitopes and induces binding to chemokine coreceptors. We therefore tested whether soluble CD4
could enhance the binding of the R5 strain SF162 to RBCs and
observed a 10-fold increase in attachment and transfer
Cell Host & Microbe 4, 52–62, July 17, 2008 ª2008 Elsevier Inc. 53
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Figure 1. DARC Binds and Transfers HIV-1 to Target Cells
(A) Representative flow-cytometric analysis of RBCs for immunostaining of DARC. RBCs were stained with the DARC monoclonal antibody anti-Fy6 (red) or an
isotype control (violet).
(B) Purified human DARC+ RBCs as shown in (A) were incubated with equal amounts of HIV-1 strains with varying coreceptor usages, washed, and added to
target NP2 cells bearing CD4 and the appropriate coreceptor (CCR5 or CXCR4). Viral transfer was quantified as the percentage of the input titer recovered
from RBCs.
(C) Time course of RT production in human PBMCs cocultured with HIV-loaded RBCs. Using methods similar to those described for (B), HIV-loaded RBCs were
cocultured with fresh-activated human PBMCs, and infection was followed by RT output over 9 days.
(D) Relative efficiency of transfer of HIV to donor cells by DARC+ versus DARC RBCs. RBCs from known DARC+ and DARC donors as shown in (A) were
incubated with PBMCs as in (C), and supernatant RT activity was measured 5 days postinfection. The bars represent the ratio of transfer efficiency of
DARC+ RBCs divided by that of DARC RBCs.
(E) Attachment of the R5X4 strain 89.6 to RBCs was inhibited by rhCCL5 (RANTES; 1 nM), rhCXCL8 (IL-8; 1 nM), and the anti-DARC monoclonal Fy6 (anti-Fy6), but
not by rhCCL3 (MIP-1aS; 1 nM). Data are presented as percentage of cell-associated RT activity compared to the untreated RBCs (gray).
(F) rhCXCL8, but not rhCCL3, inhibited transfer of infectious HIV-1 strains to fresh human PBMCs, shown as percent RT output compared to untreated RBCs 5
days postinfection.
(G) Transfer efficiency of SF162 by RBCs to target NP2.CD4.R5 was increased by the addition of 1 and 5 mg/ml of sCD4 compared to media alone (0). Data in (B),
(E), and (G) are mean ± SEM, as indicated by error bars, while data in (C), (D), and (F) are from one representative experiment from over three separate experiments
conducted.

(Figure 1G). This finding implicates specific chemokine receptor
binding sites of gp120 for adsorption of virions to DARC-positive
RBCs.
As DARC is also expressed on endothelial cell barriers, especially in the brain, we assessed the role of DARC as a functional
HIV-1 coreceptor. In NP2/CD4 cells that overexpress DARC,
none of the HIV-1 isolates shown in Figure 1B could utilize
DARC as an entry coreceptor (data not shown). These results
are consistent with previous findings (Doranz et al., 1996).
Distribution of DARC T46C in Worldwide Populations
To place the results of the genotype-HIV/AIDS phenotype study
described below in a broader evolutionary context, we first determined the distribution of the T46C DARC polymorphism in the
well-characterized populations that comprise the Human
Genome Diversity Project (HDGP)-CEPH DNA set. In the
54 Cell Host & Microbe 4, 52–62, July 17, 2008 ª2008 Elsevier Inc.

HGDP-CEPH samples, the presence of the mutated DARC
46C/C genotype was highly specific to subjects of African descent (Figure 2A). The pattern of distribution of DARC genotypes
in African Americans from the Wilford Hall Medical Center
(WHMC) cohort mimicked those found in the African CEPH
DNA samples (Figure 2B).
However, African Americans are an admixed population and
consistent with previous data (Lautenberger et al., 2000), African
Americans in the WHMC cohort also have admixture of the 46T
allele such that between 30% and 40% of African Americans are
phenotypically DARC+ (that is, have at least one 46T allele).
Therefore, in the succeeding genotype-phenotype analyses, we
accounted for possible confounding effects due to population
admixture. Based on 11 genetic markers that are differentially
distributed between European and African populations (details
provided in Supplemental Data), we predicted the self-reported
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Figure 2. Distribution of the DARC 46C/C in Worldwide Populations and Its Association with Risk of Acquiring HIV Infection in the
African-American Component of the HIV+ WHMC Cohort
(A) Distribution of and PAF for the DARC 46C/C genotype in different populations represented in the HGDP-CEPH DNA samples. Pie charts show the distribution of the 46C/C genotype in seven populations: AF (Africa), ME (Middle
East), C-S-A (Central South Asia), E-A (East Asia), EU (Europe), OC (Pacific
Ocean), and AM (America). HWp: Hardy-Weinberg test P value. y, minor allele
was absent and HWp not applicable.
(B) Distribution of the color-coded DARC 46C/C genotype in the WHMC HIVnegative (HIV) and HIV-positive (HIV+) African Americans from the WHMC
cohort. The numbers at the top of each bar represent HWp.
(C) Risk of acquiring HIV based on the T46C genotype in African-American
subjects (n = 1284) from the WHMC cohort. The diamonds and error bars
show the odds ratio and 95% confidence intervals for risk of acquiring HIV
in subjects possessing the DARC 46C/C genotype (DARC on RBCs) relative to the subjects possessing the DARC 46T/C or T/T genotype (DARC+
on RBCs). Numbers at the top of the error bars are significance values. The
results are from multivariate logistic regression analyses. Three models were
assessed: first with no covariates, then we added the CCL3L1-CCR5 GRGs
as a covariate, and finally we added the degree of population admixture as
another covariate. Number of subjects in each genotypic group is shown in
parentheses for (A) and (B) and at the bottom of (C), respectively.

ethnicity using a multivariate logistic regression model. The
model predicted the self-reported ethnicity with an overall accuracy of 98.1% (Supplemental Data). Using results from this
model, we generated a probabilistic score that reflects the ethnicity as predicted by these genetic markers. The distribution of
this score was similar among HIV+ and HIV African Americans,
indicating that the degree of admixture between these two
groups of subjects was similar (Supplemental Data). Thus, wherever appropriate, we adjusted the genotype-phenotype association of the T46C DARC polymorphism for population admixture by using this score (admixture score) as a covariate in the
statistical analyses.
DARC 46C/C Genotype and HIV Susceptibility
The DARC 46C allele was in Hardy-Weinberg (H-W) equilibrium
in HIV African Americans but was in H-W disequilibrium in HIV+
African Americans (Figure 2B). This suggested a possible asso-

ciation between the 46C allele and an altered risk of acquiring
HIV infection in African Americans. Consistent with this, the prevalence of the 46C/C genotype was greater in HIV+ than HIV
African Americans (Figure 2B), and relative to those possessing
a 46T allele (i.e., DARC 46T/T or T/C). African Americans with
a DARC 46C/C genotype had a 50% higher risk of acquiring
HIV (Figure 2C). We used this categorization of DARC T46C
genotypes because 46C/C is not associated with DARC
expression on RBCs, whereas 46T/T or T/C genotypes are.
In a previous study, we categorized CCR5 genotypes and the
copy number of CCL3L1, the most potent HIV-suppressive
CCR5-binding chemokine, into three CCL3L1-CCR5 genetic
risk groups (GRG) (Dolan et al., 2007). Although the CCL3L1
and CCR5 genotypes are key determinants of HIV acquisition
(Gonzalez et al., 2005; Kuhn et al., 2007), even after adjustment
for the transmission-modifying effects of the CCL3L1-CCR5
GRGs, the enhanced risk of acquiring HIV associated with
DARC 46C/C persisted (Figure 2C). Furthermore, when we adjusted for population admixture, the excess risk of HIV acquisition in subjects possessing the 46C/C genotype was still statistically significant, and the results of the final model suggested
that possession of this genotype is associated with 40% higher
odds of acquiring HIV than those lacking this genotype
(Figure 2C). This indicated that DARC 46C/C is an independent
determinant of increased risk of HIV acquisition in African
Americans, and the excess risk conferred by possession of
this genotype is not confounded by population admixture.
We examined how the excess risk of acquiring HIV associated
with possession of the DARC 46C/C in subjects of African descent might translate to the increased HIV burden attributable to
this genotype in worldwide populations. For this, we used the
odds for risk of HIV acquisition and the prevalence of the
DARC 46C/C genotype in the populations that comprise
the HGDP-CEPH sample to compute the population attributable
fractions (PAFs). These data (Figure 2A and Table S1) show the
PAFs for excess HIV burden attributable to DARC 46C/C is
high (11%) in African settings. To place these rather high
PAFs in context, the PAF for reduction in risk of transmission
by heterozgosity for the CCR5 D32 protective mutation in
European populations (prevalence between 10%–15%) was
only 2.6% (Table S1).
DARC 46C/C and Disease Progression
Although the DARC 46C/C genotype was associated with an
increased risk of acquiring HIV infection, within the context of established HIV infection a contrary result was observed: subjects
possessing the 46C/C genotype had a slower disease course
(Figures 3A and 3B). This relatively slow disease course was statistically more pronounced and significant when the Cox regression models included the following covariates: CCL3L1-CCR5
GRGs, which we have shown previously, have a significant impact on rate of disease progression (Dolan et al., 2007; Gonzalez
et al., 2005); the population admixture score; and the three HLA
alleles (HLA-A*68, HLA-B*57, and HLA-C*16), which we found
previously were independent determinants of disease course in
WHMC HIV+ subjects (Ahuja et al., 2008).
In addition to erythroid cells, DARC is also expressed on subsets of neurons and on endothelial cells at the blood-brain barrier
(Hadley and Peiper, 1997). DARC-negative humans display
Cell Host & Microbe 4, 52–62, July 17, 2008 ª2008 Elsevier Inc. 55
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Figure 3. Influence of the DARC T46C Polymorphism
on HIV Disease Progression in the African-American
Component of HIV + WHMC Cohort
(A) Kaplan-Meier plots for time to death based on possession of
46C/C genotype (pink) or possession of 46T/C or 46T/T
genotype (green).
(B) Results of multivariate Cox proportional hazards models for
rate of disease progression in subjects possessing the DARC
46C/C genotype (pink) relative to the subjects possessing the
DARC 46T/C or T/T genotype (green; relative hazard [RH] =
1). The following three covariates were sequentially included in
the model: (1) HLA refers to possession of the following three
HLA alleles (HLA-A*68, HLA-B*57, and HLA-C*16); (2) CCL3L1CCR5 GRGs; and (3) degree of population admixture. The
diamonds and error bars represent the RHs and 95% confidence
intervals (CI) for progression to death. Numbers at the top are
significance values. These three HLA alleles associate with
a rapid rate of disease progression in the WHMC cohort (Ahuja
et al., 2008).
(C) Kaplan-Meier plots for time to HIV-associated dementia
(HAD) based on possession of the 46C/C genotype (pink) or
possession of 46T/C or 46T/T genotype (green).
(D) The results of multivariate Cox proportional hazards modeling
similar to those shown in (B) but for the outcome of HAD.
Number of subjects in each genotypic group is shown in
parentheses for (A) and (C) and at the bottom of (B) and (D),
respectively.

reduced plasma levels of CCL2 (MCP-1) compared to DARCpositive individuals (Jilma-Stohlawetz et al., 2001; Mayr et al.,
2008), and in a previous study, we found that a CCL2 genotype
associated with increased MCP-1 expression was associated
with an increased risk of HIV-associated dementia (HAD) (Gonzalez et al., 2002). We therefore examined whether DARC expression influenced HAD. In accord with its generally protective
effect on HIV disease, DARC 46C/C also protected against the
rate of progression to HAD (Figure 3C). Furthermore, this protective effect persisted even after adjusting for the GRGs, HLA
alleles, and population admixture in multivariate models (Figure 3D). Since the 46C/C genotype affects DARC expression
only on RBCs, this finding suggested that the dominant effect
of DARC on HIV-AIDS pathogenesis is due to its expression on
RBCs and not in the brain.
Population Level Impact of DARC 46C/C
on HIV Disease
We compared CD4+ T cell loss and the rate of disease progression in African Americans who possessed or lacked the DARC
46C/C genotype versus the overall European American component of the WHMC HIV+ cohort. Consistent with the protective effects of 46C/C genotype on disease progression, the rate of
CD4+ T cell loss was significantly slower in HIV+ African Americans with the DARC 46C/C genotype compared to all other
African Americans (Figure 4A). For this reason, we inquired
whether the protective effects associated with the Africanspecific 46C/C genotype might contribute to the finding that
HIV+ African Americans have a slight survival advantage compared to European Americans (Figure 4B). A similar survival advantage during the preHAART era was also observed for HIV+
56 Cell Host & Microbe 4, 52–62, July 17, 2008 ª2008 Elsevier Inc.

African Americans in the larger Tri-Service AIDS Clinical Consortium (TACC) cohort (Silverberg et al., 2006) of which the WHMC is
part. African Americans lacking DARC 46C/C had a disease
course that was similar to that of the overall European American
component of the cohort, which was significantly faster than that
for HIV+ African Americans with the 46C/C genotype
(Figure 4C). Concordantly, the rate of CD4+ T cell loss for the overall HIV+ European Americans was similar to that of HIV+ African
Americans who lacked the 46C/C genotype (Figure 4A).
To place these results within the perspective of the highly scrutinized European-specific CCR5-D32 mutation, we compared
the disease-modifying effects associated with the DARC 46C/C
genotype in African Americans and CCR5-D32 heterozygosity
in European Americans. In subjects from the WHMC HIV+ cohort,
the survival advantage conferred by DARC 46C/C in African
Americans was comparable to that associated with CCR5-D32
heterozygosity in European Americans (Figure 4D). Furthermore,
African Americans lacking the 46C/C genotype and European
Americans lacking the CCR5-D32 mutation had similar rates of
disease progression (Figure 4D). Taken together, these findings
indicate that in the context of HIV disease, the African American-specific DARC 46C/C genotype not only mimicked the disease-retarding effects associated with the European Americanspecific CCR5-D32 mutation, but also contributed to the modest
survival advantage observed in the overall group of HIV+ African
Americans (Figure 4B).
Interactions between DARC, CCL5, and HIV
To determine whether there was an interaction between DARC,
chemokines, and HIV in vivo, we focused on a functional SNP
in CCL5 (471G/A; rs2107538), which is associated with
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Figure 4. Contribution of DARC 46C/C to Ethnicity-Specific Differences in Rates of Disease Progression in the HIV+ WHMC Cohort
(A) Time course of CD4+ T cell count decline in HIV+ subjects possessing the indicated DARC genotypes. The panel shows Loess curves for HIV+ African Americans with the indicated genotypic groups: 46C/C (pink), 46T/T, or T/C (green),and the overall group of HIV+ European Americans (blue). The average rate of
decline in CD4+ T cell count (cells/month) was estimated using GEE, and it is shown at the bottom of the panel. SE stands for standard error and P for significance
value for the difference between the rates of CD4+ T cell decline as assessed by Student’s t test and using European Americans as the reference group. Data are
from subjects who did not receive antiretroviral therapy. n, numbers of subjects; m, numbers of CD4+ T cell count measurements.
(B–D) The Kaplan-Meier plots showing the differences in rate of progression to death (B) between European Americans (blue) and African Americans (gray) in the
WHMC HIV+ cohort. (C) shows African Americans with (pink) and without (green) the DARC 46C/C genotype and European Americans (blue); (D) shows African
Americans with (pink) and without (green) the 46C/C genotype and European Americans with (brown) and without (blue) the CCR5D32 mutation. RH = 1.00
indicates the reference group used in statistical analysis. Numbers of subjects in each genotypic group in (B–D) are shown in parentheses. EAs, European
Americans. AAs, African Americans.

increased RANTES expression levels (Liu et al., 1999). In a previous study (Gonzalez et al., 2001), we found that CCL5 471A/Acontaining genotypes are associated with a faster rate of disease
progression to AIDS, but surprisingly, this association was evident only in European Americans but not African Americans.
Here, using time to death as a phenotypic endpoint, we confirmed that there were no significant differences in disease progression rates between those African Americans who were
CCL5 471A/A versus African Americans who lack this CCL5
genotype (Figure 5A). Additionally, when we compared the
disease-influencing effects associated with the CCL5 471A/A
genotype in European Americans versus African Americans,
we found that this genotype was associated with differential effects in these two populations. European Americans with CCL5
471A/A had a faster rate of disease progression than African
Americans with the same genotype (Figure 5B).
How might one explain these differential effects of the CCL5
471A/A genotype in European Americans and African Americans? Given the interactions between DARC, chemokines, and
HIV in vitro, we hypothesized that the differential effects of the
CCL5 471A/A genotype in European Americans and African
Americans might relate to differences in DARC-expression status. We postulated that the protective effects of the DARC-negative state (46C/C genotype) on HIV disease progression in African Americans mask the detrimental effect of the CCL5 471A/
A genotype in DARC-expressing African Americans (46 T/C or
T/T genotype). By contrast, as almost all European Americans
possess the DARC-expressing genotype (46T/C or T/T), the
aforementioned masking effect of the 46C/C genotype in African Americans will be absent in European Americans. If true, the
CCL5 471A/A should associate with similar disease-accelerating effects in DARC-expressing individuals, regardless of their
ethnic background.
We undertook two approaches to test our hypothesis. In the
first approach, we examined the effects of CCL5 471A/A in African Americans after accounting for DARC-expression status.

For this, we categorized the African American component of
the WHMC cohort into three DARC-CCL5 genotypic groups
(Figure 5C): group 1, African Americans lacking DARC expression (46C/C); group 2, African Americans expressing DARC
(46T/T or T/C) and lacking the CCL5 471A/A genotype; and
group 3, African Americans expressing DARC and with the
CCL5 -471A/A genotype. We found that DARC-CCL5 genotypic
groups 1 and 2 associated with similar rates of disease progression, which were significantly slower than those associated with
DARC-CCL5 genotypic group 3 (Figure 5C). Of note, these effects were more significant and pronounced after adjusting for
HLA alleles, CCL3L1-CCR5 GRGs, and the population admixture
score (Figure 5D). As a second approach, we examined the disease-modifying effects of CCL5 471A/A in European Americans and African Americans after accounting for DARC status.
These analyses showed that the CCL5 471A/A genotype associates with disease acceleration in DARC-expressing subjects
regardless of ethnicity (Figure 5E), compared to African Americans
who lack expression of DARC and possess CCL5 471A/A.
These findings affirm our hypothesis stated above and provide
a genetic-epidemiologic proof of concept for the complex interactions between DARC, chemokines, and HIV in vivo.
DISCUSSION
The association of HIV-1 virions with cell-surface factors on
macrophages and dendritic cells (DC) has been shown to protect
the virus from degradation and promote viral dissemination (Lekkerkerker et al., 2006; Levy, 2002), but the full repertoire of these
factors remains unknown. Here we demonstrate that HIV-1 adsorbs to DARC on the surface of RBCs and transfers virus to target cells, indicating that RBCs might act as carriers of infectious
HIV-1 particles to susceptible cells such as CD4+/CCR5+ T lymphocytes. Although this process was most marked for X4-tropic
strains, alteration of gp120 conformation of R5 virus by soluble
CD4+ significantly increased the binding of HIV to DARC. HIV-1
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did not infect CD4+/CCR5 or CD4+/CXCR4 cells transfected
with DARC. Collectively, these data suggest that DARC might
act like DC-SIGN on DCs (Lekkerkerker et al., 2006) in serving
as a tether rather than as a functional entry receptor, although
subsequent sequestration and formation of immunological synapses presumably do not occur with RBCs.
To determine whether the in vitro findings have in vivo relevance, we studied the impact of a polymorphism in DARC in
a well-characterized cohort of HIV-infected individuals in which
confounding factors (e.g., unequal access to health care and unequal socioeconomic status) have been minimized (Dolan et al.,
2007; Gonzalez et al., 2005). Contrary to the CCR5-D32/D32
genotype, which abrogates CCR5 expression and confers
protection against HIV transmission in Europeans, we find that
the African American-specific DARC 46C/C genotype that
abrogates DARC surface expression on RBCs is associated
with a 40% increase in the odds of HIV acquisition. Whereas,
paradoxically, once infection occurs, the DARC –46C/C genotype confers a survival advantage to African Americans that is
comparable in magnitude to the survival advantage conferred
by the CCR5-D32 genotype to European Americans. Whether
the DARC 46C/C genotype also increases the risk of infection
and conveys a survival advantage to African populations outside
the US remains unknown but would appear likely. If similar effects of the DARC 46C/C genotype on HIV acquisition were
to be conveyed in Africans, 11% of the HIV burden in these
populations may be attributable to this genotype. To validate
this hypothesis conclusively, one would need to study subjects
in Africa in whom the DARC 46C/C genotype has not attained
fixation and in whom other confounding factors, including exposure risk, had been accounted for. Unfortunately, such populations are difficult to identify in Africa because in sub-Saharan
black Africans, the 46C/C genotype is almost universal.
The sum of the in vitro and genetic epidemiologic findings demonstrates that HIV might exploit DARC to its advantage: binding
of HIV to DARC, a molecule that is expressed on one of the
most abundant cell types (RBCs), might afford a unique biological
niche that favors viral survival and persistence. Underscoring this
possibility is the observation by Hess et al., (2002), who detected
RBC-bound HIV in the absence of detectable plasma virus. Thus,
it is likely that the net effect of the relationship between DARC and
chemokines on HIV disease in vivo is likely to be much more complex, as it seems that DARC regulates the biological effects of
chemokines in three distinct ways—either through scavenging,
retention, or transportation (Comerford et al., 2007; Rot, 2005).
Hence, based on the known functions of DARC as well as the results presented herein, we hypothesize that the ultimate impact
of DARC on HIV-AIDS pathogenesis is a complex interplay between levels of DARC, circulating chemokines, and HIV virions.
The few studies that have examined the in vivo impact of
DARC genotype on free and erythrocyte-bound chemokine
levels paint a very complicated picture. The most definitive
work to date is by Jilma and colleagues (Mayr et al., 2008),
who determined plasma- and RBC-associated chemokines in
those who do (DARC+) or do not (DARC) express DARC on
RBCs, before and after administration of LPS. They found that
at baseline (pre-LPS), compared to DARC+ subjects, DARC individuals had lower plasma- and RBC-associated MCP-1 levels
(Mayr et al., 2008). Post-LPS, plasma MCP-1 levels were 2-fold
58 Cell Host & Microbe 4, 52–62, July 17, 2008 ª2008 Elsevier Inc.

lower in DARC compared to DARC+ individuals. Consequently,
DARC+ individuals—by virtue of having higher chemokine levels
during endotoxemia—have a transient proinflammatory state.
Additionally, Fukuma et al., (2003) show that DARC genotype
influences clearance mechanisms for soluble chemokines as
DARC-knockout mice have a more rapid clearance of chemokines
injected intravenously with chemokines than their wild-type counterparts. These findings underscore that DARC substantially alters
chemokine concentrations in blood with the RBC DARC- phenotype favoring a low chemokine status. These results invoke that
one has to consider the complexity of how the amount of plasma
chemokine levels and chemokines bound to erythrocyte DARC
will impact on competitive binding and displacement of HIV to
DARC as well as to CD4+ T cells. Hence, based on our results
and these human and murine investigations and knowledge that
HIV cell entry invokes a vigorous inflammatory response with
release of LPS (Douek, 2007), we propose the following model
(Figure 5F), whose confirmation will require additional studies.
Although it is tempting to speculate that akin to its sink function
for chemokines (Comerford and Nibbs, 2005), DARC might also
serve as a sink for the initial inoculum of HIV, we found that
DARC binds X4 virus more efficiently than R5 virus. Due to the
low initial inoculum and the preferential primary infection of R5 viruses compared to dual-tropic or X4 viruses, it is less likely that the
HIV adsorption/trans-infection function of DARC contributes to
the reduced risk of infection in DARC+ subjects. Instead, we suggest this is dominantly attributed by the impact of DARC on chemokine levels. The data of Mayr et al., (2008) indicate that in addition to the DARC ligands CCL2 (MCP-1) and CXCL1 (GROa),
DARC+ subjects are also likely to have higher levels of the circulating and RBC-associated HIV-suppressive chemokine CCL5 compared to DARC individuals (B. Jilma, personal communication).
Hence, at the time of initial viral exposure, when a small inoculum
of founder R5 virus is attempting to establish infection and disseminate, greater amounts of RBC-associated HIV-suppressive
chemokine might provide a relative shield for binding of HIV to
RBCs and subsequent transfer to HIV target cells (Figure 5F). Additionally, the higher plasma levels of CCL5 in DARC+ individuals
might convey a protective effect against transmission (Figure 5F).
However, once infection occurs, two events might come into
play that together confer an accelerated rate of disease progression in DARC+ individuals. First, during established infection, the
inflammatory insult conveyed by HIV (Douek, 2007) might be
greater in DARC+ than DARC individuals. This is because
DARC binds many more proinflammatory than HIV-suppressive
chemokines (Gardner et al., 2004; Rot, 2005), including those
that increase viral replication (e.g., CCL2; Monteiro de Almeida
et al., 2005). Consequently, the chemokine-driven proinflammatory state (e.g., high levels of CCL2, CCL5, and CXCL1) in
DARC+ subjects may far outweigh the HIV-suppressive effects
of high CCL5 levels, the only major HIV-suppressive chemokine
that binds to DARC. Second, by contrast to what might be observed in the setting of the initial exposure of a host to a small
viral inoculum, productive clinical HIV infection is characterized
by a high plasma viral burden, which might promote improved
virus and target-cell interactions. Consequently, after infection
is established, there is a greater probability of HIV displacing
DARC-bound chemokines, and in turn, DARC erythrocytebound HIV making physical contact with CD4-bearing target
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Figure 5. Proof-of-Concept Genetic Epidemiologic Studies Illustrating DARC-Chemokine-HIV-1 Interplay
(A) The disease-influencing effect of CCL5 471G > A SNP in HIV+ African Americans before accounting for DARC genotype. The analysis compares
CCL5 471A/A versus 471A/G or 471G/G (others).
(B) Disease-influencing effects of CCL5 471A/A genotype in European Americans and African Americans.
(C and D) Disease-influencing effects in African Americans of the three color-coded DARC-CCL5 genotypic groups. (C) shows Kaplan-Meier plots for association with
time to death. (D) shows the results of multivariate Cox proportional hazards models that examined the association of the three DARC-CCL5 genotypic groups shown
in (C) with time to death. The Cox models used the subjects possessing the DARC 46C/C genotype as the reference group. The covariates used in the models were
HLA alleles (A*68, B*57, and C*16), CCL3L1-CCR5 GRGs, and the degree of population admixture. The diamonds and error bars represent the RH and 95% confidence intervals for progression to death was obtained using Cox proportional hazards models. Numbers at the top of the error bars are significance values.
(E) Disease-influencing effects of CCL5 471A/A genotype in European Americans (EAs) or African Americans (AAs) according to DARC-expression status on RBCs
inferred by DARC genotypes (DARC expression on RBCs, i.e., DARC+ in those with 46T/T or 46T/C and DARC nonexpression on RBCs [DARC] in those with
DARC 46C/C). The number of subjects in each genotypic group is shown in parentheses for (A), (B), (E), and at the bottom of (D), respectively.
(F) A hypothetical model of DARC-influencing effects on susceptibility to risk of HIV acquisition (left) and disease progression (right) based on (1) results of
the present study, (2) published literature regarding the impact of DARC on plasma and erythrocyte bound-chemokine levels, and (3) the known role of inflammation
in HIV pathogenesis. The model is discussed in detail in the text. DARC+ and DARC are as described in (E). aDARC-bound chemokine levels are anticipated to be
lower during established HIV infection in DARC+ individuals than in DARC+ individuals at time of initial viral exposure. This is because during established HIV
infection, HIV-1 will compete for DARC-bound chemokines. bChemokine-mediated inflammatory state is shown; boxes designate the dominant effects of
DARC at time of initial exposure to virus and during established infection.
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cells, improving the efficiency of infection. Accordingly, other
studies have found that a virus bound to uninfected cells is more
stable and infectious than a similar amount of cell-free virus
(Levy, 2002). Hence, after systemic infection has been established, HIV bound to DARC-expressing RBCs might serve as a reservoir for HIV and transport to other cellular targets. The aforementioned two scenarios might explain why HIV-positive subjects who
express DARC have a faster rate of disease progression (Figure 5F). Conversely, DARC HIV-positive subjects might have
both a smaller reservoir of HIV-loaded RBCs and a reduced inflammatory state, and this could explain in part the association between the DARC 46C/C genotype and a slower disease course.
Substantiating the aforementioned model, as well the contrasting effects of DARC genotype on HIV acquisition and disease progression, we found that the genotype-phenotype relationships of
DARC+ status is remarkably similar to those of a CCL2 genotype
(2578G/G) that we showed previously was associated with
increased CCL2 expression (Gonzalez et al., 2002). Thus, it is
striking that both DARC+ status as well as the CCL2 2578G/G
genotype track higher expression levels of CCL2. They are also
both associated with contrasting effects on HIV acquisition and
disease progression, i.e., a reduced risk of HIV acquisition, but increased rate of disease progression to AIDS and HAD (this study
and Gonzalez et al., 2002). It is also noteworthy that in our previous work we only detected these associations for the CCL2
2578G/G genotype in European Americans but not African
Americans HIV+ subjects (Gonzalez et al., 2002). However, akin
to the genotype-phenotype relationships that we describe for
the CCL5 genotype before and after stratification for DARC genotype (Figures 5C–5E), we found that a disease-accelerating effect
for the CCL2 genotype was evident only in DARC+ but not
DARC African-American subjects (data not shown).
As there is extensive linkage disequilibrium (LD) around the
DARC locus (Lautenberger et al., 2000), we cannot exclude
with certainty the possibility that the effects ascribed to
the 46C/C genotype might be attributable to some other polymorphism(s)/gene(s) in LD near DARC. However, based on the
in vitro (Figure 1) and in vivo (Figure 5) data described herein,
as well as previous findings implicating a role for DARC in HIVAIDS, we suggest that the genotype-phenotype relationships
described herein are most likely directly attributable to DARC.
Nevertheless, similar studies in other cohorts are warranted to
confirm these results. Although the precise mechanisms by
which DARC imparts its effects on HIV-AIDS pathogenesis are
unclear, our findings indicate that the triangular relationship
between this chemokine-binding protein, its natural ligands
(chemokines), and pathogen (HIV) is likely to lead to biologically
complex and seemingly contrasting outcomes.
In summary, the results of our proof-of-concept geneticepidemiologic studies support a conceptual model that the interplay between DARC and chemokines might influence the
amount of free versus DARC-bound HIV available for eventual
transfer from RBCs to target cells and also chemokine levels
that promote inflammation (e.g., CCL2, CCL5, CXCL1, and
CXCL8) and compete for the binding of HIV (e.g., CCL5) to
CD4+ T cells during HIV infection. By extension, the results of
our studies indicate that failure to account for the chemokine
binding and HIV-adsorption effects of DARC might confound genetic epidemiologic studies that examine the association be60 Cell Host & Microbe 4, 52–62, July 17, 2008 ª2008 Elsevier Inc.

tween chemokine-gene polymorphisms and HIV-AIDS susceptibility in subjects of African descent. Additionally, consistent with
our previous contention (Gonzalez et al., 1999, 2005; Moore
et al., 2008), the genotype-phenotype vignettes shown here underscore further the possible impact of differentially distributed
transmission and/or disease-modifying genotypes on (1) the heterogeneity of HIV disease burden not just at the level of individuals but also populations and (2) evaluation of vaccine efficacy.
The HIV/AIDS-modifying effects of CCR5-D32 and DARC
46C, two population-specific alleles, highlight that the impact
of ancestral evolutionary factors—including infectious diseases—on the human genome are influencing outcomes of present-day infections. However, these outcomes can be complex.
For example, in addition to the DARC 46C allele, polymorphisms such as sickle-cell trait can confer infection against
malaria, which can be costly by causing genetic disease in the
homozygous state. Thus, it should not be surprising then that
what might be beneficial in one context (e.g., protection from
malaria by DARC 46C/C genotype) can be detrimental in other
settings (e.g., association between DARC 46C/C genotype and
increased risk of HIV acquisition).
Of broad interest, our studies underscore that DARC impacts
on chemokines, malaria, and HIV, a ménage à trois. However,
given the importance of the chemokine system in host defense,
immune responses, and inflammation, it will be important to
determine the contribution of DARC to the pathogenesis of other
infectious disease and inflammatory disease states.
EXPERIMENTAL PROCEDURES
Interactions between DARC and HIV-1 Virions: In Vitro
Experiments
Cells
RBCs from donors who were either DARC+ or DARC were used as virus
carriers. Target cells for infection by HIV-loaded RBCs were either purified
PBMCs or NP2 cells expressing CD4 and either CXCR4 or CCR5 as target cells
for virus-strain binding and infection experiments. The glioma NP2/CD4 cell
line has been described in detail previously (Soda et al., 1999). Cells were
maintained in Dulbecco’s modified Eagle medium (DMEM) with 5% FCS and
1% penicillin/streptomycin at 37 C with 5% CO2.
Transfer of Infectivity
Ten-thousand p24 focus-forming units (ffu) of a variety of primary isolates and
laboratory-adapted strains of HIV-1 were incubated at 37 C with 107 purified
human RBCs for 1 hour, washed extensively, and overlaid onto target cells.
For NP2/CD4 cells, viral transfer of HIV-1 was quantified as the percentage
of the input titer (p24+ve foci by in situ immunostaining) (Neil et al., 2005)
recovered from the RBCs by immunostaining target cells for p24 expression.
For PBMCs, transferred infectivity was then assessed by RT activity in the
cell supernatants at various time points postinfection. Transfer experiments
in the presence of soluble CD4 (sCD4) were performed as detailed above,
and 1 or 5 mg/ml of sCD4 was/were added to the viral inoculum prior to incubation with the RBCs.
Competitive Infectivity
Recombinant human (rh) CCL5 (RANTES), rhCXCL8 (IL-8), rhCCL3 (MIP-1aS),
and monoclonal anti-DARC antibody (anti-Fy6) in the concentrations indicated
were incubated with purified RBCs for 1 hour, then the RBCs were washed,
and infection and transfer experiments were repeated as described above.
Subjects
We genotyped HIV-1-infected (n = 1266) and noninfected (n = 2218) adult subjects recruited to the WHMC, San Antonio, TX, USA. We also genotyped the
HGDP-CEPH (n = 1064) cross-sectional sample of worldwide DNA specimens.
Detailed characteristics of the WHMC cohort and the HGDP-CEPH samples
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are described elsewhere (Dolan et al., 2007; Gonzalez et al., 2005). The protocol and consent for this study were approved by the Institutional Review
Boards at the WHMC and the University of Texas Health Science Center at
San Antonio.
SNP and Genotyping
The DARC T46C (rs2814778) SNP was genotyped by TaqMan allelic discrimination assays in the subjects described above. The nomenclature for the
DARC polymorphisms was as described by Tournamille et al., 1995 and is
based on the reference sequence AC055992. Primer and probe sequences
are available upon request from S.K.A. (ahujas@uthscsa.edu).
Statistical Methods
H-W equilibrium was assessed using the c2 test with one degree of freedom.
The risk of HIV acquisition was assessed using multivariate logistic regression analysis, while the association of the DARC genotypes with time to
death was assessed using Cox proportional hazard analysis and KaplanMeier survival plots after testing for the assumption of proportional hazards
using the Schoenfeld residuals. CD4+ T cell trajectories were depicted by
Loess curves, and rates of changes in CD4+ T cell counts were assessed
using generalized estimating equations (GEE). PAF was calculated according
to Rockhill et al., 1998. The detailed procedure of adjustments for population
admixture is provided in the Supplemental Data. STATA 7.0 (Stata Corporation, College Station, TX) software package was used to conduct the statistical analyses.
SUPPLEMENTAL DATA
Supplemental Data include one table, a supplemental note, and supplemental
references and can be found online at http://www.cellhostandmicrobe.com/
cgi/content/full/4/1/52/DC1/.
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